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Background: An increased incidence of fungal infections, both invasive and superficial, has been witnessed over
the last two decades. Candida species seem to be the main etiology of nosocomial fungal infections worldwide
with Candida albicans, which is commensal in healthy individuals, accounting for the majority of invasive Candida
infections with about 30-40% of mortality.
Results: New aromatic and heterocyclic esters 5a-k of 1-aryl-3-(1H-imidazol-1-yl)propan-1-ols 4a-d were successfully
synthesized and evaluated for their anti-Candida potential. Compound 5a emerged as the most active congener
among the newly synthesized compounds 5a-k with MIC value of 0.0833 μmol/mL as compared with fluconazole
(MIC value >1.6325 μmol/mL). Additionally, molecular modeling studies were conducted on a set of anti-Candida
albicans compounds.
Conclusion: The newly synthesized esters 5a-k showed more potent anti-Candida activities than fluconazole.
Compounds 7 and 8 revealed significant anti-Candida albicans activity and were able to effectively satisfy the
proposed pharmacophore geometry, using the energy accessible conformers (Econf < 20 kcal/mol).
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An increased incidence of fungal infections, both invasive
and superficial, has been witnessed over the last two de-
cades. Such infections are the major cause of morbidity
and mortality especially in immune-compromised individ-
uals such as patients with cancer or AIDS and in organ
transplant cases [1,2]. Candida species seem to be the
main etiology of nosocomial fungal infections worldwide
with Candida albicans, which is commensal in healthy
individuals [3], accounting for the majority of invasive
Candida infections with about 30-40% of mortality [4].
Toxicity, low efficacy rates, and drug resistance limit
the clinical use of the available antifungal agents [5].
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reproduction in any medium, provided the ornew potent broad spectrum antifungal agents with fewer
side effects.
The clinically used antifungal drugs belong to the
classes of polyenes (such as amphotericin B and nysta-
tin), echinocandins (such as caspofungin), allylamines
(such as naftifine and terbinafine), fluoropyrimidines
(such as 5-fluorocytosine) and azoles (such as micona-
zole and fluconazole) (Figure 1) [6-8]. Azole antifungal
drugs featuring either an imidazole (e.g. miconazole,
econazole, ketoconazole and clotrimazole) or a 1,2,4-
triazole moiety (e.g. fluconazole and itraconazole) are
the most widely used antifungal agents in clinics be-
cause of their safety profile and high therapeutic index
[9]. The mechanism of action of azole antifungals relies
on their ability to inhibit synthesis of sterols in fungi via
inhibiting cytochrome P450-dependent 14α-lanosterol
demethylase through binding to the heme cofactor of
the cytochrome CYP51 [10,11].
An evaluation of the literature revealed that many
imidazole-containing antifungal agents have a spacer of
two carbon atoms between the imidazole pharmacophoreLtd. This is an open access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Chemical structures of common antifungal azole drugs.
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about imidazole-containing antifungals having a three-
carbon atom bridge between the imidazole pharmaco-
phore and the aromatic moiety is available [12,13]. Add-
itionally, it has been well documented that some aryl and
arylalkyl esters of 2-(1H-imidazol-1-yl)-1-phenylethanols
displayed anti-Candida albicans activity more than that of
miconazole [14].
Accordingly, we report herein the synthesis, anti-
Candida activity and molecular modeling studies of
certain new aryl/heterocyclic esters 5a-k of 1-aryl-3-(1H-
imidazol-1-yl)propan-1-ols 4a-d bearing a three-carbon
atom linker between the imidazole pharmacophore and
the aromatic moiety.
Experimental
Melting points were determined on a Gallenkamp melting
point apparatus, and are uncorrected. NMR spectra were
acquired on a Bruker NMR spectrometer operating at
500 MHz for 1H and 125.76 MHz for 13C at the Research
Center, College of Pharmacy, King Saud University, Saudi
Arabia. TMS was used as an internal standard and chem-
ical shift values were recorded in ppm on the δ scale. The
1H NMR data were represented as follows: chemical shifts,
multiplicity (s. singlet, d. doublet, t. triplet, m. multiplet,
br. broad) and number of protons. The 13C NMR data
were represented as chemical shifts and type of carbon.
Mass spectra were measured on an Agilent Triple Quadru-
pole 6410 QQQ LC/MS with ESI (Electrospray ionization)
source. Silica gel TLC (thin layer chromatography)
plates from Merck (silica gel precoated aluminium
plates with fluorescent indicator at 245 nm) were used
for thin layer chromatography. Visualization wasperformed by illumination with a UV light source
(254 nm). Column chromatography was carried out on
silica gel 60 (0.063-0.200 mm) obtained from Merck
and chloroform/methanol (18:1) was used as the solvent
system. Our research group reported previously the
synthesis and characterization of compounds 6–11 [12].
Fluconazole was obtained from Shouguang-Fukang
Pharmaceutical Ltd., Shandong, China. The antifungal
discs containing 25 μg fluconazole were purchased from
ROSCO (Neo-Sensitabs, Taastrup, Denmark).
General procedure for preparation of the ketones 3a-d
A mixture of the appropriate acetophenone 1a-d
(200 mmol), dimethylamine hydrochloride (260 mmol)
and paraformaldehyde (260 mmol) in absolute ethanol
(35 mL) and a catalytic amount of concentrated hydro-
chloric acid (0.5 mL). The reaction mixture was heated
to reflux for two hours, cooled and acetone (200 mL)
was added. The precipitated Mannich bases 2a-d were
filtered off and dried. Compounds 2a-d (100 mmol)
were dissolved in water (100 mL) and imidazole (200 mmol)
was added. The reaction mixture was heated to reflux
for five hours, cooled and the precipitated solids were
collected by filtration to give the ketones 3a-d which
were pure enough to be used in the next step. The
synthesized compounds 3a-d gave the same analyses as
reported previously [12,13,15,16].
General procedure for preparation of the alcohols 4a-d
Sodium borohydride (130 mmol) was added portionwise
to a solution of the appropriate ketone 3a-d (43 mmol)
in methanol (150 mL). The reaction mixture was stirred
at ambient temperature for 18 hours. Methanol was
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dissolved in ethyl acetate (200 mL) and washed with
water (3 × 50 mL). The organic phase was separated,
dried (Na2SO4) and evaporated under vacuum to afford
alcohols 4a-d which were subjected to the subsequent
esterification step without any further purification. The
synthesized alcohols 4a-d gave the same analyses as
reported previously [12,13,17,18].
General procedure for the synthesis of the target esters
5a-k
DMAP (400 mg) was added to a stirred solution of the
appropriate acid (7 mmol) and EDCI HCl (7.3 mmol) in
DCM (75 mL). The appropriate alcohol 4a-d (6.9 mmol)
was added to the stirred reaction mixture and stirring
was continued for a further 18 h at room temperature.
The reaction mixture was washed successively with
water (2 × 20 mL), 10% NaHCO3 solution (2 × 15 mL),
and water (2 × 15 mL). The organic layer was separated,
dried (Na2SO4) and evaporated under reduced pressure
and the residue was purified either by recrystallisation
(for solids) or column chromatography (for oils).
3-(1H-Imidazol-1-yl)-1-phenylpropyl 3,4-dichlorobenzoate
(5a)
Yield 65%; pale yellow viscous oil; IR (KBr): ν (cm-1)
3049, 2929, 1722 (C =O), 1505, 1266, 734; 1H NMR
(CDCl3): δ 2.27-2.34 (m, 1H, -CH2-CH2-N), 2.47-2.54
(m, 1H, -CH2-CH2-N), 3.91-3.96 (m, 2H, -CH2-CH2-N),
5.85-5.88 (m, 1H, C6H5-CH-O-), 6.83 (s, 1H, -N-CH =
CH-N=), 6.97 (s, 1H, -N-CH = CH-N=), 7.19-7.29 (m,
5H, Ar-H), 7.35 (s, 1H, -N-CH =N-), 7.34 (d, J = 8.4 Hz,
1H, Ar-H), 7.76, (dd, J = 8.4, 1.95 Hz, 1H, Ar-H.), 7.99
(d, J = 1.93 Hz, 1H, Ar-H); 13C NMR (CDCl3): δ 36.4
(−CH2-CH2-N), 42.4 (−CH2-CH2-N), 73.5 (C6H5-C-O-),
117.7 (−N-CH= CH-N=), 125.3, 127.7, 127.8, 127.9,
128.6, 128.8, 129.7, 130.5, 132.0 (−N-CH =CH-N=, Ar-
CH, Ar-C), 136.0 (−N-CH=N-), 136.9, 137.6 (Ar-C),
162.8 (C =O); MS m/z (ESI): Calcd for C19H16Cl2N2O2:
375.25. Found: 375.1 [M]+.
1-(4-Chlorophenyl)-3-(1H-imidazol-1-yl)propyl 4-
chlorobenzoate (5b)
Yield 30%; pale yellow viscous oil; IR (KBr): ν (cm-1)
3052, 2985, 1717 (C =O), 1507, 1264, 738; 1H NMR
(CDCl3): δ 2.33-2.39 (m, 1H, -CH2-CH2-N), 2.52-2.59
(m, 1H, -CH2-CH2-N), 4.09-4.13 (m, 2H, -CH2-CH2-N),
5.87-5.90 (m, 1H, C6H5-CH-O-), 6.92 (s, 1H, -N-CH =
CH-N=), 7.09 (s, 1H, -N-CH = CH-N=), 7.19-7.29 (m,
5H, Ar-H, -N-CH =N-), 7.34-7.38 (m, 2H, Ar-H), 7.89-
7.92 (m, 2H, Ar-H); 13C NMR (CDCl3): δ 37.4 (−CH2-
CH2-N), 44.4 (−CH2-CH2-N), 73.2 (C6H5-C-O-), 119.4
(−N-CH=CH-N=), 127.5, 127.7, 128.7, 128.8, 129.0,
129.2, 131.1 (−N-CH =CH-N=, Ar-CH, Ar-C), 137.3(−N-CH=N-), 139.5, 140.2 (Ar-C), 164.9 (C =O); MS




Yield 28%; pale yellow viscous oil; IR (KBr): ν (cm-1)
3050, 2961, 1716 (C =O), 1513, 1265, 739; 1H NMR
(CDCl3): δ 2.35-2.42 (m, 1H, -CH2-CH2-N), 2.58-2.65
(m, 1H, -CH2-CH2-N), 3.82 (s, 3H, OCH3), 4.01-4.08 (m,
2H, -CH2-CH2-N), 5.92-5.95 (m, 1H, C6H5-CH-O-), 6.93
(d, J = 9.0 Hz, 2H, Ar-H), 6.94 (s, 1H, -N-CH = CH-N=),
7.09 (s, 1H, -N-CH = CH-N=), 7.34 (d, J = 8.5 Hz,
2H, Ar-H), 7.43 (d, J = 8.5 Hz, 2H, Ar-H), 7.54 (s, 1H, -N-
CH =N-), 7.97 (d, J = 8.5 Hz, 2H, Ar-H); 13C NMR
(CDCl3): δ 37.4 (−CH2-CH2-N), 43.6 (−CH2-CH2-N),
55.3 (OCH3), 73.8 (C6H5-C-O-), 114.3 (Ar-CH), 118.8
(−N-CH = CH-N=), 127.9, 128.4, 128.8, 129.5, 130.8,
131.1 (−N-CH=CH-N=, Ar-CH, Ar-C), 137.0 (−N-CH=
N-), 139.8, 159.9 (Ar-C), 164.8 (C =O); MS m/z (ESI):




Yield 36%; pale yellow viscous oil; IR (KBr): ν (cm-1)
3051, 2982, 1719 (C =O), 1506, 1264, 731; 1H NMR
(CDCl3): δ 2.27 (s, 3H, CH3), 2.28-2.34 (m, 1H, -CH2-
CH2-N), 2.47-2.54 (m, 1H, -CH2-CH2-N), 3.92-3.98 (m,
2H, -CH2-CH2-N), 5.84-5.87 (m, 1H, C6H5-CH-O-), 6.85
(s, 1H, -N-CH = CH-N=), 6.99 (s, 1H, -N-CH = CH-N=),
7.11 (d, J = 8.0 Hz, 2H, Ar-H), 7.19 (d, J = 8.0 Hz,
2H, Ar-H), 7.34 (d, J = 8.5 Hz, 2H, Ar-H), 7.45 (s, 1H, -N-
CH =N-), 7.89 (d, J = 8.5 Hz, 2H, Ar-H); 13C NMR
(CDCl3): δ 21.2 (CH3), 37.5 (−CH2-CH2-N), 43.6 (−CH2-
CH2-N), 73.9 (C6H5-C-O-), 118.8 (−N-CH=CH-N=),
126.4, 128.3, 128.9, 129.4, 129.6, 131.1 (−N-CH=CH-N=,
Ar-CH, Ar-C), 135.9, 137.0, 138.6, 139.8 (−N-CH =
N-, Ar-C), 164.8 (C = O); MS m/z (ESI): Calcd for
C20H19ClN2O2: 354.83. Found: 355.2 [M + 1]
+.
3-(1H-Imidazol-1-yl)-1-phenylpropyl 4-fluorobenzoate (5e)
Yield 80%; pale yellow viscous oil; IR (KBr): ν (cm-1)
3051, 2979, 1721 (C =O), 1506, 1265, 738; 1H NMR
(CDCl3): δ 2.27-2.34 (m, 1H, -CH2-CH2-N), 2.46-2.53
(m, 1H, -CH2-CH2-N), 3.91-3.99 (m, 2H, -CH2-CH2-N),
5.88-5.90 (m, 1H, C6H5-CH-O-), 6.84 (s, 1H, -N-CH =
CH-N=), 6.98 (s, 1H, -N-CH = CH-N=), 7.04 (m, 2H,
Ar-H), 7.23-7.29 (m, 5H, Ar-H), 7.40 (s, 1H, -N-CH =N-),
7.96-7.99, (m, 2H, Ar-H); 13C NMR (CDCl3): δ 37.7
(−CH2-CH2-N), 43.5 (−CH2-CH2-N), 73.9 (C6H5-C-O-),
115.7 (d, J = 22.0 Hz, Ar-CH), 118.8 (−N-CH=CH-N=),
126.1, (d, J = 2.4 Hz, Ar-C), 126.3 (Ar-CH), 128.7, 128.9
(−N-CH=CH-N=, Ar-CH), 129.7 (Ar-CH), 132.3 (d, J =
9.4 Hz, Ar-CH), 137.1 (−N-CH=N-), 139.0 (Ar-C), 164.7
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for C19H17FN2O2: 324.35. Found: 325.2 [M+ 1]
+.
3-(1H-Imidazol-1-yl)-1-phenylpropyl 4-methylbenzoate (5f)
Yield 52%; pale yellow solid, m.p. 60–62°C (isopropanol);
IR (KBr): ν (cm-1) 3049, 2976, 1717 (C =O), 1506, 1266,
739; 1H NMR (CDCl3): δ 2.27-2.32 (m, 1H, -CH2-CH2-N),
2.34 (s, 3H, CH3), 2.45-2.52 (m, 1H, -CH2-CH2-N),
3.92-4.01 (m, 2H, -CH2-CH2-N), 5.89-5.92 (m, 1H,
C6H5-CH-O-), 6.85 (s, 1H, -N-CH = CH-N=), 6.99 (s,
1H, -N-CH = CH-N=), 7.18 (d, J = 7.8 Hz, 2H, Ar-H),
7.23-7.31 (m, 5H, Ar-H), 7.42 (s, 1H, -N-CH = N-), 7.87,
(d, J = 8.1 Hz, 2H, Ar-H); 13C NMR (CDCl3): δ 21.7
(CH3), 37.9 (−CH2-CH2-N), 43.5 (−CH2-CH2-N), 73.4
(C6H5-C-O-), 118.8 (−N-CH = CH-N=), 126.3, 127.1,
128.5, 128.9, 129.3, 129.5, 129.7 (−N-CH = CH-N=, Ar-
CH, Ar-C), 137.0 (−N-CH =N-), 139.4, 144.2 (Ar-C),
165.7 (C = O); MS m/z (ESI): Calcd for C20H20N2O2:
320.38. Found: 321.2 [M + 1]+.
3-(1H-Imidazol-1-yl)-1-phenylpropyl 4-(trifluoromethyl)
benzoate (5g)
Yield 49%; white solid, m.p. 98–100°C (isopropanol); IR
(KBr): ν (cm-1) 3053, 2979, 1717 (C =O), 1506, 1269,
736; 1H NMR (CDCl3): δ 2.29-2.36 (m, 1H, -CH2-CH2-N),
2.49-2.56 (m, 1H, -CH2-CH2-N), 3.91-3.99 (m, 2H, -CH2-
CH2-N), 5.89-5.92 (m, 1H, C6H5-CH-O-), 6.84 (s, 1H, -N-
CH = CH-N=), 6.98 (s, 1H, -N-CH = CH-N=), 7.23-7.31
(m, 5H, Ar-H), 7.39 (s, 1H, -N-CH = N-), 7.62 (d, J =
8.2 Hz, 2H, Ar-H), 8.06, (d, J = 8.5 Hz, 2H, Ar-H); 13C
NMR (CDCl3): δ 37.5 (−CH2-CH2-N), 43.4 (−CH2-CH2-
N), 74.5 (C6H5-C-O-), 118.7 (−N-CH=CH-N=), 125.6 (d,
J = 3.4 Hz, CF3), 126.4, 128.8, 128.9, 129.7, 130.1, 133.0
(−N-CH=CH-N=, Ar-CH,), 134.7, 134.9, 137.0, 138.7
(−N-CH=N-, Ar-C), 164.4 (C =O); MS m/z (ESI): Calcd




Yield 68%; white solid, m.p. 102–104°C (isopropanol); IR
(KBr): ν (cm-1) 3121, 2921, 1716 (C =O), 1511, 1299,
775; 1H NMR (CDCl3): δ 2.25-2.32 (m, 1H, -CH2-CH2-
N), 2.44-2.52 (m, 1H, -CH2-CH2-N), 3.92-4.01 (m, 2H, -
CH2-CH2-N), 5.87-5.89 (m, 1H, C6H5-CH-O-), 6.44 (dd,
J = 1.7, 3.5 Hz, 1H, furan-H), 6.85 (s, 1H, -N-CH = CH-
N=), 6.99 (s, 1H, -N-CH = CH-N=), 7.14 (dd, J = 0.5,
3.5 Hz, 1H, furan-H), 7.22-7.29 (m, 5H, Ar-H), 7.43 (s,
1H, -N-CH =N-), 7.51-7.52, (m, 1H, furan-H); 13C NMR
(CDCl3): δ 37.7 (−CH2-CH2-N), 43.4 (−CH2-CH2-N),
73.6 (C6H5-C-O-), 112.0 (furan-CH), 118.6 (furan-CH),
118.8 (−N-CH=CH-N=), 126.4, 128.7, 128.9, 129.5 (−N-
CH =CH-N=, Ar-CH), 137.0 (−N-CH=N-), 138.4 (Ar-




Yield 86%; off white solid, m.p. 96–98°C (isopropanol);
IR (KBr): ν (cm-1) 3059, 2979, 1724 (C =O), 1506, 1265,
733; 1H NMR (CDCl3): δ 2.39-2.47 (m, 1H, -CH2-CH2-N),
2.60-2.68 (m, 1H, -CH2-CH2-N), 4.02-4.11 (m, 2H, -CH2-
CH2-N), 6.00-6.03 (m, 1H, C6H5-CH-O-), 6.95 (s, 1H, -N-
CH = CH-N=), 7.09 (s, 1H, -N-CH =CH-N=), 7.35-7.41
(m, 6H, Ar-H, Pyridine-H5), 8.81 (dd, J = 1.5, 5.0 Hz, 1H,
Pyridine-H6), 7.54 (s, 1H, -N-CH =N-), 8.28-8.29 (m, 1H,
Pyridine-H4), 9.26 (d, J = 1.5 Hz, 1H, Pyridine-H2); 13C
NMR (CDCl3): δ 37.5 (−CH2-CH2-N), 43.5 (−CH2-CH2-
N), 74.4 (C6H5-C-O-), 118.7 (−N-CH=CH-N=), 123.4
(pyridine-C5), 125.8, 126.4, 128.8, 128.9, 129.6 (−N-CH=
CH-N=, Ar-CH, pyridine-C3), 137.0, 138.6 (−N-CH =
N-, Ar-C), 150.9 (pyridine-C2), 153.8 (pyridine-C6),
164.4 (C = O); MS m/z (ESI): Calcd for C18H17N3O2:
307.35. Found: 308.2 [M + 1]+.
3-(1H-Imidazol-1-yl)-1-phenylpropyl pyridine-4-
carboxylate (5j)
Yield 60%; pale yellow viscous oil; IR (KBr): ν (cm-1)
3051, 2981, 1730 (C =O), 1506, 1264, 737; 1H NMR
(CDCl3): δ 2.32-2.39 (m, 1H, -CH2-CH2-N), 2.52-2.59
(m, 1H, -CH2-CH2-N), 3.93-4.02 (m, 2H, -CH2-CH2-N),
5.89-5.92 (m, 1H, C6H5-CH-O-), 6.85 (s, 1H, -N-CH =
CH-N=), 6.99 (s, 1H, -N-CH = CH-N=), 7.25-7.34 (m,
5H, Ar-H), 7.46 (s, 1H, -N-CH =N-), 7.76 (d, J = 6.0 Hz,
2H, Pyridine-H3, H5), 8.72 (d, J = 6.0 Hz, 2H, Pyridine-H2,
H6); 13C NMR (CDCl3): δ 37.4 (−CH2-CH2-N), 43.5
(−CH2-CH2-N), 74.8 (C6H5-C-O-), 118.7 (−N-CH=CH-
N=), 122.8 (pyridine-C3, C5), 126.4, 128.9, 128.9, 129.0
(−N-CH=CH-N=, Ar-CH), 137.0, 138.4 (−N-CH=N-, Ar-
C), 150.8 (pyridine-C2, C6), 164.2 (C =O); MS m/z (ESI):




Yield 80%; white solid, m.p. 96–98°C (isopropanol); IR
(KBr): ν (cm-1) 3050, 2981, 1717 (C =O), 1506, 1265, 736;
1H NMR (CDCl3): δ 2.34-2.41 (m, 1H, -CH2-CH2-N),
2.52-2.59 (m, 1H, -CH2-CH2-N), 4.00-4.09 (m, 2H, -CH2-
CH2-N), 5.90-5.93 (m, 1H, C6H5-CH-O-), 6.94 (s, 1H, -N-
CH = CH-N=), 6.97 (d, J = 4.0 Hz, 1H, thiophene-H), 7.09
(s, 1H, -N-CH = CH-N=), 7.35-7.41 (m, 5H, Ar-H), 7.52
(s, 1H, -N-CH =N-), 7.63 (d, J = 4.0 Hz, 1H, thiophene-H);
13C NMR (CDCl3): δ 37.7 (−CH2-CH2-N), 43.4 (−CH2-
CH2-N), 74.2 (C6H5-C-O-), 118.7 (−N-CH=CH-N=),
126.3, 127.5, 128.7, 128.9, 129.6 (−N-CH = CH-N=,
thiophene-CH, Ar-CH), 131.3 (thiophene-CH), 133.6
(thiophene-C), 137.0 (−N-CH=N-), 137.9 (thiophene-C),
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Stock solutions (1000 μg/mL) of fluconazole and/or the
synthesized compounds 5a-k and 6–11 were prepared
in 100% dimethyl sulfoxide and were diluted with sterile
distilled water. All antifungal discs were stored at −80°C
until used.
Media
Liquid RPMI 1640 medium supplemented with L-
glutamine was purchased from Sigma-Aldrich Co. (St.
Louis, MO, USA) and was added to 2% sodium bicar-
bonate and 0.165 M morpholinepropane sulfonic acid
(MOPS) from Dojindo Laboratories (Kumamoto, Japan)
then adjusted to pH 7.0. Sabouraud Dextrose Agar
(SDA) and Brain Heart Infusion (BHI) were purchased
from Difco Laboratories (Detroit. Michigan, USA). Potato
Dextrose Agar (PDA) was purchased from Eiken Chemical
Co. Ltd. (Tokyo, Japan).
Organisms
Two clinical isolates of Candida species, one identified as
C. albicans and the other as C. tropicalis, were obtained
from King Khaled Hospital, Riyadh, Saudi Arabia. The
yeasts were stored at −70°C in BHI with glycerol 5% until
tested.
Preparation of inocula
Preparation of inocula for the broth microdilution testing
was performed in accordance with CLSI documents M27-
A2 [19] with RPMI 1640 medium. Isolates of Candida
species were subcultured at 35°C for 48 h on PDA plates.
Yeast cells were recovered from at least five 1-mm-
diameter colonies and suspended in 5 mL of sterile sa-
line. The suspension was mixed for 15 s with a vortex
mixer, and the turbidity of each suspension was adjusted
to a 0.5 McFarland standard (corresponding to 1.3 ×106
to 5.3 × 106 CFU/mL) at a wavelength of 530 nm ac-
cording to the reported method [19]. Each suspension
was diluted 1,000-fold with RPMI 1640 medium to give
a final inoculum of 1.3 × 103 to 5.3 × 103 CFU/mL.
Disk diffusion assay
The disk diffusion assay was performed as described previ-
ously [20]. Cell suspensions of the previously chosen
yeasts were adjusted to a 0.5 McFarland standard (corre-
sponding to 5 × 106 CFU/mL). A 100 μl suspension of
each tested strain was spread uniformly onto SDA plates.
Whatmann filter paper disks with a diameter of 6 mm
were impregnated with 1000 μg of the synthesized com-
pounds 5a-k. After the disks were allowed to dry, theywere placed onto the surface of the inoculated agar plates
together with the standard antifungal discs which were
then incubated at 35°C. Experiments were performed in
duplicate and diameters of inhibition zones were mea-
sured at 24 hours.
Antifungal susceptibility studies
The previously prepared yeast inocula (100 μl) were added
to each well of 96-well flat-bottom microdilution plates;
each well contained 100 μl of twofold serial dilutions of the
reference standard and/or the synthesized compounds 5a-k
and 6–11 ranging from 1 μg/mL to 500 μg/mL in RPMI
1640 medium. After each plate was incubated at 35°C for
48 h, the turbidity of each well was measured at 490 nm
with a microplate ELISA reader. The MICs of the Candida
species were recorded as the lowest concentration at
which a prominent decrease (50-80%) in turbidity relative
to the turbidity of the growth control was observed.
Pharmacophore modeling
LigandScout (version 3.0) was used to derive the 3D
chemical feature-based pharmacophores from the struc-
tural data of the compounds under study 5a-k and 6–11,
using the default settings [21]. Compounds 5a, 5d, 5j,
6–8, 10 and 11 were included as a training set in the
modeling study. Prior to the generation of pharmacophore
hypotheses, the training set compounds, which were
converted to 3D structure, were used to generate diverse
conformations. The LigandScout program was used to
generate the conformations, using the BEST conformation
model generation method. Other parameters, such as the
maximum number of 250 conformers and an energy
threshold value of 20 kcal/mol above the local energy
minimum, were chosen during conformations generation.
The pharmacophoric features, hydrogen bond acceptor
(HBA), hydrogen bond donor (HBD) and hydrophobic
feature (HY), were selected to produce a reliable pharma-
cophore model for the experimental results during the
pharmacophore hypothesis generation. Compounds 5b,
5c, 5e-i, 5k and 9, were selected as a test set for pharma-
cophore validation. This method is used to elucidate
whether the generated pharmacophore hypothesis is profi-
cient to predict the activities of compounds other than the
training set and classify them correctly in their activity
scale. The conformation generation for the test set com-
pounds was carried out in a similar way, as the training set
compounds using the BEST conformational analysis algo-
rithm, implemented within LigandScout. Subsequently,
pharmacophore mapping was conducted on the resulting
conformations [21].
Docking procedure
All molecular modeling studies were performed on a PC
using Windows Vista Home Premium Intel(R) Core(TM)2
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generated in the protonated state that would be found
under physiological conditions. The coordinates of the
X-ray structure of 14-α-sterol demethylase (CYP51)
active site domain complexed with fluconazol (1EA1)
was obtained from the Protein Data Bank [23]. The co-
crystallized ligand was docked in its original protein
structure using the default settings of the program. A
10 Å sphere around the centre of the active site was
defined as the binding pocket for the docking runs. All
torsion angles in each compound were allowed to rotate
freely.Results and discussion
Chemistry
The synthetic strategy to prepare the target compounds
5a-k and their intermediates is illustrated in Schemes 1
and 2. Preparation of the pivotal ketones 3a-d began by
allowing the appropriate acetophenone 1a-d to react
with dimethylamine hydrochloride and paraformaldehyde
in the presence of a catalytic amount of concentrated
hydrochloric acid. The formed Mannich base hydrochlo-
rides 2a-d were transformed into the ketones 3a-d via
refluxing with imidazole in water (Scheme 1).
Ketones 3a-d were reduced to their respective alcohols
4a-d using sodium borohydride in methanol. The result-
ing alcohols 4a-d were subjected to esterification with the
appropriate carboxylic acid derivatives using ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDCI
HCl) in the presence of 4-dimethylaminopyridine (DMAP)
to yield the target compounds 5a-k (Scheme 2). The





1a-d                                                              2a-d           
R R
Compound N
1a, 2a, 3a 
1b, 2b, 3b 
1c, 2c, 3c 
1d, 2d, 3d 
Scheme 1 Synthesis of the ketones 3a-d. Reagents and conditions: i) HN
ii) Imidazole, water, reflux, 5 h, 44-77% yield.confirmed via IR, 1H NMR, 13C NMR and mass spec-
tral data.In vitro anti-Candida activity
The gold standard azole antifungal, fluconazole, has
been used as a first line of treatment for fungal infec-
tions especially those caused by C. albicans, but its ex-
tensive use in the clinics has led to the development of
resistance [24]. The in vitro anti-Candida activity of the
synthesized imidazole-containing esters 5a-k was evalu-
ated against two clinical isolates of Candida: C. albicans
and C. tropicalis, which were practically resistant to flu-
conazole (MIC >1.6325 μmol/mL). The obtained data,
expressed as diameter of the inhibition zone (DIZ) and
minimum inhibition concentration (MIC) for the test
compounds 5a-k and for the reference drug, flucona-
zole, are presented in Table 1.
It was previously reported that the alcohol 4a displayed a
weak antifungal activity [12] which is consistent with the
proposed pharmacophore model of azole antifungals
(Figure 2) [25]. This azole antifungal pharmacophore model
incorporates at least three binding points, namely iron
coordinating group, first aromatic group and a second aro-
matic group, to elicit optimum activity. Alcohol 4a pos-
sesses only two binding points, imidazole moiety and an
aromatic moiety B adjacent to it. Accordingly, addition of a
third binding point via aromatic esterification of the alcohol
functionality of 4a should enhance its antifungal activity.
The preliminary anti-Candida potential of the test com-
pounds 5a-k was evaluated using DIZ assay and the re-
sults are illustrated in Table 1. Compounds 5a-k showed a
promising anti-Candida profile with DIZ = 14–17 mmCH3)2 HCl N
O
Nii







(CH3)2HCl, (CH2O)n, conc. HCl, ethanol, reflux, 2 h; 47-95% yield
Table 1 Anti-Candida activity of the target compounds 5a-k against Candida albicans and Candida tropicalis
Compound no Candida albicans Candida tropicalis
DIZ ± SD* MIC (μmol/mL)** DIZ ± SD* MIC (μmol/mL)**
5a 17 ± 1.1 0.0833 13 ± 0.9 0.3331
5b 16 ±1.1 0.6662 14 ±1.0 0.3331
5c 16 ±1.0 0.6742 14 ± 0.9 0.3371
5d 14 ± 0.5 0.3523 16 ±1.1 0.3523
5e 16 ±1.6 0.3854 16 ± 0.6 0.3854
5f 16 ± 0.9 0.3902 11 ± 0.9 0.7803
5g 14 ± 0.0 0.6678 14 ± 0.0 0.3339
5h 17 ± 0.9 0.4218 17 ± 0.8 0.4218
5i 14 ± 0.0 0.8134 16 ± 1.0 0.8134
5j 14 ± 0.0 0.8134 19 ± 1.0 0.4067
5k 16 ± 0.6 0.7208 14 ± 0.5 0.3604
Fluconazole 15 ± 0.5 >1.6325 16 ± 0.5 >1.6325
*The arithmetic mean of the inhibition zone diameters in mean ± standard deviation. **The lowest concentration of the compound that produced 50-80%
microbial growth inhibition (μmol/mL).
Compound No. R R1
3a, 4a, 5a H 3,4-Cl2-C6H3
3b, 4b, 5b Cl 4-Cl-C6H4
3c, 4c, 5c OCH3 4-Cl-C6H4




5h H 2-C4H3O 
5i H 3-C5H4N 
5j H 4-C5H4N 
5k H 5-Cl-C4H2S 
N
O






3a-d                                                                      4a-d                                                                     5a-k
R1
R R R
Scheme 2 Synthesis of the target compounds 5a-k. Reagents and conditions: i) NaBH4, methanol, rt, 24 h; 60-78% yield ii) Appropriate
carboxylic acid, EDCI HCl, DMAP, DCM, rt, 18 h, 28-86% yield.












Figure 2 Schematic representation of the pharmacophore of
azole antifungal aromatic esters.
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spectively. Compounds 5a and 5h were the most active
congeners against C. albicans while compound 5j was the
most active candidate against C. tropicalis. Consequently,
MIC values of the test compounds 5a-k were determined
in order to gain insight into their anti-Candida activity as
compared with that of fluconazole, the gold standard anti-
fungal drug.
The synthesized aromatic esters of 4a, compounds 5a
and 5e-g, showed better anti-Candida activity (MICs =
0.0833-0.6678 and 0.3331-0.7803 μmol/mL towards C.
albicans and C. tropicalis, respectively) than that of flu-
conazole (MIC >1.6325 μmol/mL). Additionally, esteri-
fication of the alcohol functionality of 4a with aromaticFigure 3 The pharmacophore model mapping and predictive values oisoster heterocyclic carboxylic acids gave compounds
5h-k, which exhibited good anti-Candida activity
(MICs = 0.4218-0.8134 and 0.3604-0.8134 μmol/mL to-
wards C. albicans and C. tropicalis, respecively) being
more potent than fluconazole (MIC >1.6325 μmol/mL).
It was previously documented that esterification of 4a
with 4-chlorobenzoic acid gave compound 7 (Figure 3)
which showed potent anti-Candida activity [12]. Substi-
tution of aromatic ring B of compound 7 with chloro,
methoxy and/or methyl groups gave compounds 5b, 5c
and 5d, respectively. Compounds 5b-d exhibited anti-
Candida albicans activity (MICs = 0.3523-0.6742 μmol/
mL) weaker than that of their parent compound 7 (MIC =
0.0114 μmol/mL) but they are more potent than flucona-
zole (MIC >1.6325 μmol/mL) (Figure 3).
Pharmacophore modeling
In view of the excellent in vitro results, additional in silico
studies were done to support the in vitro anti-Candida
studies. The anti-Candida potential of the synthesized
compounds 5a-k and 6–11 (Figure 3), against Candida
albicans, was selected for a pharmacophore modeling
study. Compounds 5a, 5d, 5j, 6–8, 10 and 11 were used
as a training set while compounds 5b, 5c, 5e-i, 5k and 9
were used as a test set. On the assumption that the active
compounds bind in a similar fashion to the active site, we
employed the LigandScout program [26] to evaluate com-
mon features essential for activity, and the hypothetical
geometries adopted by these ligands in their most activef compounds 5a-k and 6-11 as anti-Candida albicans agents.
Figure 5 A chart representing the negative logarithm of the
minimal inhibitor concentration in μmol/mL (dependent value)
against LigandScout program output fit value (independent
value).
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pharmacophore model generation based on shared chem-
ical features. Conformations within 20 kcal/mol were sub-
mitted to the alignment procedure. The successful
pharmacophore run resulted in generation of 10 models.
Based on its highest score and its mapping into all training
set molecules, the chosen model was statistically consid-
ered to be the best hypothesis and was selected for further
investigation and analysis. The proposed pharmacophore
model is shown in Figure 4 and contains six chemical
features: four hydrophobic regions and two hydrogen
bond acceptors.
All of the synthesized compounds, 5a-k and 6–11,
were mapped onto the model, and the orientation of the
mapped compound relative to the proposed pharmaco-
phore was scored ("fit value") (Figure 3). This provided a
quick validation of the model with mapped compounds
showing good agreement with the fit value and bio-
logical activity (Figure 3). The highly active compounds
showed a range of fit values of 90.8–92.43, while the
remaining compounds with moderate to weak activity,
showing fit values of 78.06–87.09. This initial correlation
encouraged us to generate a linear model, based on “fit
value” to predict the biological activity of the test set
compounds. The generated model (Equation 1) was used
successfully to predict the activity of the test set com-
pounds (Figures 3 and 5).
− logMIC μmol=mLÞ ¼ 0:1269 fit valueð Þ−10:168ð
ð1Þ
n ¼ 8; SE ¼ 0:496; R ¼ 0:810; R2 ¼ 0:657
Where n: number of compounds; R: multiple correlation
coefficients; SE: standard error.Figure 4 Proposed pharmacophore model of growth inhibition activiFigure 6 shows the alignment of the hypothesis model
with the most active compounds 7 and 8, and Figure 7
shows the alignment of the hypothesis model with the
weakly active compounds 5j and 10. A closer look at the
mapped structures (Figure 6) reveals the importance of
certain structural features for activity. The presence of a
hydrophobic substituent at the para position of the
benzoate moiety appears to be preferable for the anti-
Candida albicans activity of the tested compounds.
Unsubstituted benzoate or para-substituted with polar
group (Figure 7) affects badly on the fit value of the
compounds to the pharmacophore model, which is also
reflected on its experimental weak activity.
Docking procedure
A docking study was undertaken using Dock6.4 [22] in
order to investigate the possible interactions between
the designed compounds and the active site of the
CYP51 enzyme. The X-ray structure of the enzymety against Candida albicans (red, HBA; yellow, hydrophobic).
Figure 7 Aligned poses of compounds 5j and 10. (a) Best aligned pose of the less active compound 5j (MIC 0.8134 μmol/mL) overlaid onto
the pharmacophore model (model-1). (b) Best aligned pose of the less active compound 10 (MIC 1.4230 μmol/mL) overlaid onto the
pharmacophore model (model-1).
Figure 6 Aligned poses of compounds 7 and 8. (a) Best aligned pose of compound 7 (MIC 0.0114 μmol/mL) superposed with the query
(model-1). (b) Best aligned pose of compound 8 (MIC 0.0104 μmol/mL) fitted inadequately with the query (model-1).
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tein data bank; PDB code: 1EA1 [23]. The RMSD value
difference of 0.431 Å of the pose of the non-restricted
redocking of FCZ into the X-ray structure of the CYP51
from the co-crystallized FCZ also confirmed the approach
(Figure 8).Figure 8 Superimposition of the co-crystallized FCZ (from
1AE1.pdb, colored magenta) and the re-docked FCZ (colored
white).The binding site includes a hydrophobic pocket delin-
eated by the side chains of Gln 72, Tyr 76, Phe 78, Met
79, Phe 83, Arg 96, Met 99, Leu 100, Ser 252, Phe 255,
Ala 256, His 259, Leu 321, Ile 323, Met 433 and Val 434
(Figure 9). The docking pose of compound 8 as an ex-
ample of the designed compounds showed that the imid-
azole scaffold of compound 8 is oriented in the same
binding site as that of the triazole moiety of the co-
crystallized FCZ with 1EA1 (Figure 9). The imidazole
ring in compound 8 is oriented near the heme residue in
the binding site delineated by the Ala 256, His 259, Thr
260 while the phenyl ring of the benzoate moiety is
sandwiched between the phenyl ring of Tyr 76 and side
chain of Leu 321.
Conclusion
Synthesis, characterization and anti-Candida activity of
certain new aryl/heterocyclic esters 5a-k of 1-aryl-3-
(1H-imidazol-1-yl) propan-1-ols 4a-d have been success-
fully achieved. The synthesized esters 5a-k exhibited anti-
Candida activity better than that of the gold standard
antifungal drug, fluconazole. Compound 5a emerged as the
most active congener (MIC = 0.0833 μmol/mL) among the
Figure 9 Compound 8 (coloured magenta) docked into 1AE1.
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http://journal.chemistrycentral.com/content/7/1/168newly synthesized compounds 5a-k being nearly 20 times
more potent than fluconazole (MIC >1.6325 μmol/mL) as
an anti-Candida albicans agent. Compound 5a showed
a slightly weaker activity against Candida albicans
than that of our previously reported compounds 7 and
8 (MIC = 0.0117 and 0.0104 μmol/mL, respectively).
Molecular modeling studies on a set of anti-Candida
albicans compounds were able to effectively satisfy the
proposed pharmacophore geometry.
Additional file
Additional file 1: 1H and 13C NMR spectra of compounds 5c, 5e, 5f,
5g-i and 5k.
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